(4S)-2-oxothiazolidine-4-carboxylic acid | 77273-78-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S)-2-oxothiazolidine-4-carboxylic acid
• 英文别名: (S)-(+)-2-Oxothiazolidine-4-carboxylic acid；L-2-oxothiazolidine-4-carboxylic acid；(4S)-2-oxo-1,3-thiazolidine-4-carboxylic acid
• CAS: 77273-78-0
• 化学式: C₄H₅NO₃S
• 分子量: 147.155
• InChiKey: BMLMGCPTLHPWPY-UWTATZPHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  氨乙硝酸 、 (4S)-2-oxothiazolidine-4-carboxylic acid 在 焦碳酸二乙酯 作用下， 生成 (4S)-N-(2-Nitrooxyethyl)-2-oxothiazolidine-4-carboxamide
  参考文献：
  名称：

  Synthesis and collateral dilator activity of nitroxyalkylamides having direct or latent sulfhydryl moieties

  摘要：

  To develop an orally active, long-acting nitrate that does not induce tolerance, nitroxyalkyl compounds were prepared and their activities evaluated by the use of carotid collaterals in anesthetized dogs. A compound having a favorable pharmacological profile, that is, long-lasting collateral vasodilatation and little hypotension, and lack of nitrate tolerance, was chosen for further evaluation. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00199-9
• 作为产物：
  描述：

  (-)-2-oxo-4-thiazolidine carboxylic acid 在 Pseudomonas sp. No_. 1-24 、 甘油 作用下， 以 水 为溶剂， 以37.6%的产率得到(4S)-2-oxothiazolidine-4-carboxylic acid
  参考文献：
  名称：

  Mochizuki, Kazuya; Yamazaki, Yoshimitsu; Hosono, Kuniaki, Agricultural and Biological Chemistry, 1990, vol. 54, # 2, p. 543 - 544

  摘要：

  DOI：

文献信息

• Total Synthesis of (+)-18-<i>epi</i>-Latrunculol A: Development of a Synthetic Route
  作者：Brett D. Williams、Amos B. Smith

  DOI：10.1021/jo501733m

  日期：2014.10.3

  The evolution of an enantioselective total synthesis of (+)-18-epi-latrunculol A, a congener of the marine-sponge-derived latrunculins A and B, is reported. Key steps include a late-stage Mitsunobu macrolactonization to construct the 16-membered macrolactone, a mild Carreira alkynylation to unite the northern and southern hemispheres, a diastereoselective, acid-mediated δ-hydroxy enone cyclization/equilibration

  报告了 (+)-18- epi -latrunculol A（海洋海绵衍生的 latrunculins A 和 B 的同系物）的对映选择性全合成的演变。关键步骤包括后期 Mitsunobu 大环内酯化以构建 16 元大环内酯、温和的 Carreira 炔基化以统一北半球和南半球、非对映选择性、酸介导的 δ-羟基烯酮环化/平衡序列，以及功能组-耐受交叉复分解以获得烯酮环化前体。
• Thiazolidone compounds and method of using the same as a vasodilator
  申请人：Sankyo Company, Limited

  公开号：US05298516A1

  公开（公告）日：1994-03-29

  Compounds of formula (I): ##STR1## wherein W represents a sulfur atom and X represents a group of formula --N(R.sup.1)--, or W represents a group of formula --N(R.sup.1)-- and X represents a sulfur atom; R.sup.1 is hydrogen, alkyl or aralkyl; R.sup.2 and R.sup.3 are each hydrogen, alkyl, aralkyl, aryl or aromatic heterocyclic; R.sup.4 is hydrogen, alkyl or aralkyl; and A is alkylene which is optionally substituted by carboxy; and pharmaceutically acceptable salts and esters thereof, have a valuable vasodilatory activity.

  式(I)的化合物：##STR1##其中W代表硫原子，X代表式--N(R.sup.1)--的基团，或者W代表式--N(R.sup.1)--的基团，X代表硫原子；R.sup.1是氢、烷基或芳基烷基；R.sup.2和R.sup.3分别是氢、烷基、芳基烷基、芳基或芳香杂环；R.sup.4是氢、烷基或芳基烷基；A是烷基，可以选择性地被羧基取代；以及其药学上可接受的盐和酯，具有有价值的血管扩张活性。
• Oxazolidinone compounds and method of using the same as a vasodilator
  申请人：Sankyo Company, Ltd.

  公开号：US05356918A1

  公开（公告）日：1994-10-18

  Compounds of formula (I): ##STR1## wherein W represents an oxygen atom and X represents a group of formula --N(R.sup.1)--; R.sup.1 is hydrogen, alkyl or aralkyl; R.sub.2 and R.sup.3 are each hydrogen, alkyl, aralkyl, aryl or aromatic heterocyclic; R.sup.4 is hydrogen, alkyl or aralkyl; and A is alkylene which is optionally substituted by carboxy; and pharmaceutically acceptable salts and esters thereof, have a valuable vasodilatory activity.

  公式（I）的化合物：##STR1## 其中W代表氧原子，X代表公式--N（R.sup.1）-的基团; R.sup.1是氢，烷基或芳基烷基; R.sub.2和R.sup.3分别是氢，烷基，芳基烷基，芳基或芳香族杂环; R.sup.4是氢，烷基或芳基烷基; A是可选地取代羧基的烷基;以及其药学上可接受的盐和酯，具有有价值的血管扩张活性。
• HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS
  申请人：Muhammad Naweed

  公开号：US20110263545A1

  公开（公告）日：2011-10-27

  The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.

  本发明提供了肝保护醋氨酚共价偶联物，其含有醋氨酚基团与第二基团共价结合，第二基团可能作为肝保护剂对抗醋氨酚肝毒性。此外，醋氨酚共价偶联物可能具有改善的水溶性，相对于醋氨酚的给药方式，更适合于静脉和其他剂型的使用。本发明还提供了使用肝保护醋氨酚共价偶联物治疗对醋氨酚具有反应的疾病或病况的方法（如发热、疼痛和缺血性损伤），以及套装和单元剂量。
• ——
  作者：

  DOI：——

  日期：——